Scientists Defend Trial Questioning Remdesivir’s Covid Benefits

Scientists Defend Trial Questioning Remdesivir’s Covid Benefits

Scientists defended a World Health Organization trial showing that the antiviral treatment remdesivir doesn’t save the lives of Covid-19 patients after drugmaker Gilead Sciences Inc. criticized the findings.

Remdesivir, which U.S. President Donald Trump received when he was diagnosed with the coronavirus, failed to reduce mortality in a global trial sponsored by the agency, called Solidarity. Gilead said the data have “not undergone rigorous review.”

Remdesivir, originally developed to treat Ebola, has been in demand for Covid since a U.S. government trial showed it reduced patients’ recovery time by four days. The WHO study called those results into question, said Richard Peto, a statistician at the University of Oxford who reviewed the trial results.